Non-Hodgkin Lymphoma Therapeutics Market

Global Non-Hodgkin Lymphoma Therapeutics Market by Types of Therapy (Chemotherapy, Targeted Therapy, Radiation Therapy, Immunotherapy, and Others), Cell Types (T-cell Lymphoma and B-cell Lymphoma), Distribution Channels (Hospital Pharmacies, Drug Stores, Online Pharmacies, and Retail Pharmacies), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-2036
  • Author: Growth Market Reports
  • Rating: 4.9
  • Total Reviews: 3
  • No. Of Pages: 215
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global non-Hodgkin lymphoma therapeutics market size was valued at USD 6 billion in 2020 and is estimated to surpass USD 12 billion by 2028, expanding at a CAGR of 8% during the forecast period, 2021–2028. The growth of the market is attributed to the rising prevalence of non-lymphomas Hodgkin's (NHL).

Non-Hodgkin Lymphoma Therapeutics Market

Lymphoma is cancer that affects lymphocytes, which are a type of white blood cell. This usually happens in the lymphatic system, bone marrow, lymph nodes, spleen, blood, and other organs. It is one of the most dangerous and life-threatening cancers.  Non-Hodgkin's lymphomas are a type of blood cancer that includes a wide range of lymphomas but does not include Hodgkin's lymphomas. NHL ranges from minor to deadly. Night sweats, skin irritation, recurrent high fever, shortness of breath, appetite loss and weight loss, and painless sweating of lymph nodes located throughout the body are all common signs of the disease.

Market Trends, Drivers, Restraints, and Opportunities

  • Rising prevalence of non-Hodgkin's lymphomas (NHL) and other cancers, increasing R&D procedures, rising public awareness about the impacts of NHL, and increased medical and healthcare expenditure and infrastructure are estimated to propel the market expansion in the coming years.
  • Increasing global market revenue by improving a disorder’s prognosis, due to the modern therapeutics, high cure rates, and effective diagnostic procedures frequently work hand in hand for better treatment outcomes, which individuals are more inclined to accept advanced treatment.
  • High cost of NHL medications, as well as the multiple side-effects that are associated with them, are projected to impede the market growth.
  • Rigorous regulatory standards and the high cost of R&D and treatment possess as key challenges that can hamper the market expansion during the forecast period.

Scope of the Report

The report on the global non-Hodgkin lymphoma therapeutics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Global Non-Hodgkin Lymphoma Therapeutics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Types of Therapy (Chemotherapy, Targeted Therapy, Radiation Therapy, Immunotherapy, and Others), Cell Types (T-cell Lymphoma and B-cell Lymphoma), Distribution Channels (Hospital Pharmacies, Drug Stores, Online Pharmacies, and Retail Pharmacies)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Accredo Health Group Inc.; Baxter International Inc.; AstraZeneca; Bayer AG; Eli Lilly and Co.; Celgene Corp.; Teva Pharmaceuticals Industries Ltd; F. Hoffmann La-Roche Ltd.; Spectrum Pharmaceuticals; GlaxoSmithKline PLC; Seattle Genetics Inc.; Novartis; and  Pfizer

Global Non-Hodgkin Lymphoma Therapeutics Market Segment Insights

Radiation therapy segment is projected to account for a major key share

Based on types of therapy, the global non-Hodgkin lymphoma therapeutics market is segmented into chemotherapy, targeted therapy, radiation therapy, and others. The radiation therapy segment is expected to account for a key share of the market during the forecast period owing to the use of high-energy beams or particles to kill cancer cells. It can be administered from an external source (external beam radiation) or from within the body (brachytherapy). Radiation treatments are usually administered five days a week for a few weeks.

When this type of lymphoma is only discovered in one place of the body, radiation therapy is most successful. For improved results in advanced lymphomas, radiation therapy is utilized in combination with chemotherapy. It mostly aids in the relief of lymphoma-related symptoms.

Non-Hodgkin Lymphoma Therapeutics Market

B-cell Lymphoma segment expected to register at a significant pace

On the basis of cell types, the market is bifurcated into T-cell lymphoma and B-cell lymphoma. The B-cell lymphoma is expected to constitute a key share of the market in the coming years due to a majority of non-Hodgkin lymphoma cases and is expected to maintain its market share over the forecast period, which accounts for B-cell lymphoma's dominance in the global market for non-Hodgkin lymphoma treatment.

On the other hand, the T-cell lymphoma segment is anticipated to expand at a rapid pace during the forecast period owing to the fairly rare appearance of T-cell lymphoma, which results in a lower number of patients than B-cell lymphoma, which is likely to restrain the segment's expansion.

Non-Hodgkin Lymphoma Therapeutics Market

Hospital Pharmacies segment is anticipated to expand at a substantial CAGR

In terms of distribution channels, the global non-Hodgkin lymphoma therapeutics market is fragmented into hospital pharmacies, drug stores, online pharmacies, and retail pharmacies. The hospital pharmacies are expected to hold a key share of the market during the forecast period owing to the majority of medications used to treat lymphoma can only be given intravenously. This necessitates the use of qualified medical personnel to ensure that the treatment instructions are followed correctly. This ensures that medications are administered safely and also that clinical outcomes are favourable.

However, the online pharmacies segment is anticipated to expand at a rapid pace during the forecast period due to several advantages such as the convenience of completing prescriptions from the comfort of one's own home.

Asia Pacific is expected to dominate the market

On the basis of regions, the market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. Asia Pacific is anticipated to expand at a healthy CAGR during the forecast period. The regional market growth can be attributed to the result of variables such as increased access to healthcare services in the region and an increase in the prevalence of NHL. Many manufacturing companies are investing in developing novel drug therapies to fulfill the growing demand for treatments as the incidence and prevalence of non-Hodgkin lymphoma rise year after year. However, North America is expected to exhibit a rapid growth rate in the coming years due to technological advancements and rising NHL incidences in the country.

Non-Hodgkin Lymphoma Therapeutics Market

Segments

Segments Covered in the Report

The global non-Hodgkin lymphoma therapeutics market has been segmented on the basis of

Types of Therapy

  • Chemotherapy
  • Targeted Therapy
  • Radiation Therapy
  • Immunotherapy
  • Others

Cell Types

  • T-cell Lymphoma
  • B-cell Lymphoma

Distribution Channels

  • Hospital Pharmacies
  • Drug Stores
  • Online Pharmacies
  • Retail Pharmacies

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Accredo Health Group Inc.
  • Baxter International Inc.
  • AstraZeneca; Bayer AG
  • Eli Lilly and Co.
  • Celgene Corp.
  • Teva Pharmaceuticals Industries Ltd
  • F. Hoffmann La-Roche Ltd.
  • Spectrum Pharmaceuticals
  • GlaxoSmithKline PLC
  • Seattle Genetics Inc.
  • Novartis
  • Pfizer

Competitive Landscape

Key players competing in the global non-Hodgkin lymphoma therapeutics market include Accredo Health Group Inc.; Baxter International Inc.; AstraZeneca; Bayer AG; Eli Lilly and Co.; Celgene Corp.; Teva Pharmaceuticals Industries Ltd; F. Hoffmann La-Roche Ltd.; Spectrum Pharmaceuticals; GlaxoSmithKline PLC; Seattle Genetics Inc., Novartis; and  Pfizer.

Non-Hodgkin Lymphoma Therapeutics Market

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Non-Hodgkin Lymphoma Therapeutics Market Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Non-Hodgkin Lymphoma Therapeutics Market Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Non-Hodgkin Lymphoma Therapeutics Market Market - Supply Chain
  4.5. Global Non-Hodgkin Lymphoma Therapeutics Market Market Forecast
     4.5.1. Non-Hodgkin Lymphoma Therapeutics Market Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Non-Hodgkin Lymphoma Therapeutics Market Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Non-Hodgkin Lymphoma Therapeutics Market Market Absolute $ Opportunity
5. Global Non-Hodgkin Lymphoma Therapeutics Market Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Non-Hodgkin Lymphoma Therapeutics Market Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Non-Hodgkin Lymphoma Therapeutics Market Demand Share Forecast, 2019-2026
6. North America Non-Hodgkin Lymphoma Therapeutics Market Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Non-Hodgkin Lymphoma Therapeutics Market Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Non-Hodgkin Lymphoma Therapeutics Market Demand Share Forecast, 2019-2026
7. Latin America Non-Hodgkin Lymphoma Therapeutics Market Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Non-Hodgkin Lymphoma Therapeutics Market Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Non-Hodgkin Lymphoma Therapeutics Market Demand Share Forecast, 2019-2026
8. Europe Non-Hodgkin Lymphoma Therapeutics Market Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Non-Hodgkin Lymphoma Therapeutics Market Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Non-Hodgkin Lymphoma Therapeutics Market Demand Share Forecast, 2019-2026
9. Asia Pacific Non-Hodgkin Lymphoma Therapeutics Market Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Non-Hodgkin Lymphoma Therapeutics Market Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Non-Hodgkin Lymphoma Therapeutics Market Demand Share Forecast, 2019-2026
10. Middle East & Africa Non-Hodgkin Lymphoma Therapeutics Market Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Non-Hodgkin Lymphoma Therapeutics Market Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Non-Hodgkin Lymphoma Therapeutics Market Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Non-Hodgkin Lymphoma Therapeutics Market Market: Market Share Analysis
  11.2. Non-Hodgkin Lymphoma Therapeutics Market Distributors and Customers
  11.3. Non-Hodgkin Lymphoma Therapeutics Market Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. Accredo Health Group Inc. Baxter International Inc. AstraZeneca; Bayer AG Eli Lilly and Co. Celgene Corp. Teva Pharmaceuticals Industries Ltd  

Segments Covered in the Report

The global non-Hodgkin lymphoma therapeutics market has been segmented on the basis of

Types of Therapy

  • Chemotherapy
  • Targeted Therapy
  • Radiation Therapy
  • Immunotherapy
  • Others

Cell Types

  • T-cell Lymphoma
  • B-cell Lymphoma

Distribution Channels

  • Hospital Pharmacies
  • Drug Stores
  • Online Pharmacies
  • Retail Pharmacies

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Accredo Health Group Inc.
  • Baxter International Inc.
  • AstraZeneca; Bayer AG
  • Eli Lilly and Co.
  • Celgene Corp.
  • Teva Pharmaceuticals Industries Ltd
  • F. Hoffmann La-Roche Ltd.
  • Spectrum Pharmaceuticals
  • GlaxoSmithKline PLC
  • Seattle Genetics Inc.
  • Novartis
  • Pfizer

Key players competing in the global non-Hodgkin lymphoma therapeutics market include Accredo Health Group Inc.; Baxter International Inc.; AstraZeneca; Bayer AG; Eli Lilly and Co.; Celgene Corp.; Teva Pharmaceuticals Industries Ltd; F. Hoffmann La-Roche Ltd.; Spectrum Pharmaceuticals; GlaxoSmithKline PLC; Seattle Genetics Inc., Novartis; and  Pfizer.

Non-Hodgkin Lymphoma Therapeutics Market

Buy Report